Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock

Celcuity, Inc. (NASDAQ:CELC) Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares of the company’s stock, valued at $10,802,700. This trade represents a 18.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Celcuity Stock Down 2.4%

NASDAQ:CELC opened at $109.42 on Friday. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The stock’s fifty day moving average is $104.24 and its two-hundred day moving average is $72.14. The stock has a market capitalization of $5.06 billion, a price-to-earnings ratio of -29.81 and a beta of 0.25. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.13. Research analysts anticipate that Celcuity, Inc. will post -2.62 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CELC. Craig Hallum lifted their price objective on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC set a $95.00 price target on shares of Celcuity in a research note on Monday, October 20th. Jefferies Financial Group upped their price objective on Celcuity from $108.00 to $134.00 and gave the stock a “buy” rating in a research report on Tuesday, December 2nd. HC Wainwright reiterated a “neutral” rating and issued a $94.00 target price (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. Finally, Wells Fargo & Company assumed coverage on Celcuity in a research note on Friday, December 12th. They set an “overweight” rating and a $126.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $105.25.

Hedge Funds Weigh In On Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of CELC. Ogorek Anthony Joseph NY ADV increased its holdings in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock valued at $66,000 after buying an additional 109 shares during the last quarter. US Bancorp DE increased its holdings in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the last quarter. Rhumbline Advisers raised its position in shares of Celcuity by 1.2% during the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares in the last quarter. M&T Bank Corp lifted its stake in Celcuity by 14.3% during the fourth quarter. M&T Bank Corp now owns 4,671 shares of the company’s stock worth $465,000 after purchasing an additional 583 shares during the last quarter. Finally, WoodTrust Financial Corp lifted its stake in Celcuity by 10.8% during the fourth quarter. WoodTrust Financial Corp now owns 6,207 shares of the company’s stock worth $619,000 after purchasing an additional 607 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.